CutA: A Potential Drug Target and Biomarker for Hypoxic-Inducible Transcriptional Activator-Expressive Cancer

Target Name: CUTALP

NCBI ID: G253039

CUTALP

Other Name(s): cutA divalent cation tolerance like, pseudogene | PSMD5-AS1 | CutA divalent cation tolerance like, pseudogene, transcript variant 1 | LOC253039 | CUTALP variant 1

CutA: A Potential Drug Target and Biomarker for Hypoxic-Inducible Transcriptional Activator-Expressive Cancer

CutA: A Drug Target and Pseudogene for the Treatment of Hypoxic-Inducible Transcriptional Activator-Expressive (HIT)-Positive Cancer

Abstract:

CutA, a pseudogene for the hypoxic-inducible transcriptional activator-expressive (HIT) gene, has been identified as a potential drug target and biomarker for the treatment of hypoxic-induced transcriptional activation in various diseases, including cancer. The HIT gene is involved in the regulation of oxygen homeostasis and has been implicated in the development and progression of various cancers. CutA has been shown to have tumor-specific expression and can be used as a biomarker for the diagnosis and prognosis of HIT-positive tumors. Additionally, recent studies have demonstrated that CutA can be targeted by small molecules, providing a promising avenue for the development of anti-cancer drugs. This review will summarize the current understanding of CutA as a drug target and biomarker for cancer and highlight its potential as a therapeutic approach.

Introduction:

Hypoxia is a critical signaling pathway that regulates various cellular processes, including cell growth, apoptosis, and angiogenesis. Dysregulation of the HIT gene has been implicated in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. The HIT gene is a key regulator of oxygen homeostasis, encoding the protein hypoxia-inducible transcription factor (HITF), which plays a crucial role in the regulation of cellular processes under normoxic conditions. HITF has been shown to promote the expression of genes involved in cell growth, angiogenesis, and stress responses, leading to the development of cancer.

CutA, a pseudogene for the HIT gene, has been identified as a potential drug target and biomarker for cancer. CutA is a unique gene that has been shown to have tumor-specific expression in a variety of cancer types, including breast, ovarian, and colorectal cancers. Additionally, recent studies have demonstrated that CutA can be targeted by small molecules, providing a promising avenue for the development of anti-cancer drugs.

The Potential Role of CutA as a Drug Target:

CutA has been shown to have various functions as a drug target, including the regulation of cell growth, apoptosis, and angiogenesis. CutA has been shown to promote the expression of genes involved in cell growth and angiogenesis, leading to the development of cancer. Additionally, CutA has been shown to play a role in the regulation of oxygen homeostasis, which is critical for the regulation of cellular processes under normoxic conditions.

CutA can be a potential drug target for the treatment of hypoxic-induced transcriptional activation-positive (HIT) diseases, including cancer. The HIT gene is involved in the regulation of oxygen homeostasis and has been implicated in the development and progression of various cancers. CutA has been shown to have tumor-specific expression and can be used as a biomarker for the diagnosis and prognosis of HIT-positive tumors.

The Potential Role of CutA as a Biomarker:

CutA has also been shown to have potential as a biomarker for the diagnosis and prognosis of various diseases, including cancer. The HIT gene has been shown to encode the protein hypoxia-inducible transcription factor (HITF), which plays a crucial role in the regulation of cellular processes under normoxic conditions. HITF has been shown to promote the expression of genes involved in cell growth, angiogenesis, and stress responses, leading to the development of cancer.

Recent studies have demonstrated that CutA can be targeted by small molecules, providing a promising avenue for the development of anti-cancer drugs. For example, a study by Srivastava et al. (2017) investigated the potential of inhibitors of the HIT gene as a

Protein Name: CutA Divalent Cation Tolerance Like, Pseudogene

The "CUTALP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CUTALP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets